- Previous Close
26.25 - Open
24.27 - Bid 24.06 x --
- Ask 24.19 x --
- Day's Range
23.47 - 24.89 - 52 Week Range
23.47 - 154.76 - Volume
847 - Avg. Volume
1,623 - Market Cap (intraday)
9.325B - Beta (5Y Monthly) 2.23
- PE Ratio (TTM)
-- - EPS (TTM)
-8.58 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.comRecent News: MRNA.VI
View MorePerformance Overview: MRNA.VI
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRNA.VI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRNA.VI
View MoreValuation Measures
Market Cap
9.93B
Enterprise Value
4.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.41
Price/Book (mrq)
1.01
Enterprise Value/Revenue
1.39
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-110.04%
Return on Assets (ttm)
-15.14%
Return on Equity (ttm)
-28.77%
Revenue (ttm)
3.24B
Net Income Avi to Common (ttm)
-3.56B
Diluted EPS (ttm)
-8.58
Balance Sheet and Cash Flow
Total Cash (mrq)
7.02B
Total Debt/Equity (mrq)
6.85%
Levered Free Cash Flow (ttm)
-3.09B